In a 14-year-old patient with dengue whose platelet count fails to rise after single donor platelet (SDP) transfusion, what investigations are indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Investigations for Persistent Thrombocytopenia After SDP in Dengue

First, confirm true platelet refractoriness by obtaining a post-transfusion platelet count 1 hour (or 10 minutes) after the SDP transfusion, then calculate the corrected count increment (CCI) - if CCI is <5,000 after a second ABO-compatible transfusion, initiate investigations for the underlying cause of refractoriness. 1

Initial Assessment: Confirm Refractoriness

Before extensive workup, you must establish that true platelet refractoriness exists:

  • Obtain post-transfusion platelet count at 1 hour (or 10 minutes) after SDP completion 1
  • Calculate the expected increment: For children, expect approximately 3,500/m²/unit absolute increment 1
  • Calculate CCI: CCI = (absolute increment × body surface area in m²) / (number of platelets transfused × 10¹¹) 1
  • Define refractoriness: CCI <5,000 after at least two ABO-compatible transfusions stored <72 hours 1

Critical pitfall: A single poor increment does not define refractoriness - patients may respond adequately to subsequent transfusions 1. Do not pursue extensive investigations after just one failed transfusion.

Investigations to Initiate

1. Rule Out Non-Immune Causes First 2

These are more common in dengue and must be excluded before pursuing alloimmunization workup:

  • Clinical assessment for:

    • Active bleeding/hemorrhage (check for plasma leakage, hemoconcentration)
    • Shock or hemodynamic instability
    • Splenomegaly (ultrasound if not already done)
    • Disseminated intravascular coagulation (DIC)

  • Laboratory tests:

    • Coagulation profile: PT/INR, aPTT, fibrinogen, D-dimer to assess for DIC 3
    • Complete blood count with peripheral smear: Look for platelet clumping (pseudothrombocytopenia), schistocytes (microangiopathy)
    • Liver and renal function: Assess disease severity and organ involvement

2. Verify Transfusion Compatibility 1, 2

  • Confirm ABO compatibility: ABO-incompatible platelets (e.g., A platelets to O recipient) can compromise post-transfusion increments 1
  • Verify platelet storage time: Platelets stored >72 hours have reduced viability 1

3. Assess for Alloimmunization (If Above Causes Excluded) 1, 2

While less common in dengue, if refractoriness persists after ruling out clinical causes:

  • HLA class I antibody testing: Approximately 90% of alloimmunized patients have detectable HLA antibodies 2, 1
  • Panel-reactive antibody (PRA) score: Quantifies degree of sensitization 1

Important context: In dengue, alloimmunization is uncommon, especially with leukoreduced products. One study found only 8% of refractory cases had detectable alloantibodies 1.

4. Consider Post-Dengue ITP 4, 5

If thrombocytopenia persists beyond the expected dengue recovery phase (typically 7-10 days):

  • Bone marrow examination: Shows increased megakaryocytes with adequate platelet production but peripheral destruction 4, 5
  • Antiplatelet antibody testing: If available
  • Serial platelet monitoring: ITP following dengue can manifest weeks to months after initial infection 5

Key distinction: Dengue-associated thrombocytopenia typically resolves with disease recovery. Persistent thrombocytopenia beyond 2 weeks post-discharge warrants investigation for secondary ITP 5.

Practical Algorithm

  1. Immediate (within 1 hour of transfusion):

    • Post-transfusion platelet count
    • Calculate CCI

  2. If CCI <5,000 on first transfusion:

    • Give second ABO-compatible SDP
    • Recheck post-transfusion count and CCI

  3. If CCI <5,000 after second transfusion:

    • Clinical assessment: Bleeding, shock, splenomegaly
    • Labs: Coagulation profile (PT/INR, aPTT, fibrinogen, D-dimer), peripheral smear
    • Verify: ABO compatibility, platelet storage time

  4. If clinical/non-immune causes excluded:

    • HLA antibody testing
    • Consider bone marrow examination if thrombocytopenia persists beyond expected dengue recovery

  5. If thrombocytopenia persists >2 weeks post-dengue recovery:

    • Bone marrow examination for post-dengue ITP 4, 5

Critical Caveats

  • Dengue-specific considerations: The thrombocytopenia in dengue is primarily due to bone marrow suppression and increased peripheral destruction from the viral infection itself, not alloimmunization 6, 7
  • Transfusion risks: Recent evidence suggests prophylactic platelet transfusion in dengue may increase mortality and bleeding risk 8, so refractoriness workup should focus on identifying treatable causes rather than pursuing aggressive transfusion strategies
  • Timing matters: Distinguish between acute dengue-related refractoriness (investigate non-immune causes) versus persistent post-recovery thrombocytopenia (investigate for ITP) 5

References

8
Research

Platelet Transfusion in Dengue-Associated Thrombocytopenia: A Systematic Review and Meta-Analysis.

Revista da Sociedade Brasileira de Medicina Tropical, 2026

Related Questions

In a dengue patient with a platelet count of 40 × 10⁹/L and petechiae on the legs, should I give a platelet transfusion?
In a 40‑year‑old stable dengue patient on day 5 of illness with severe thrombocytopenia (platelet count 8 × 10³/µL) and no bleeding, should platelet transfusion be given?
In dengue fever with warning signs, under what clinical or laboratory conditions is blood transfusion indicated, and which specific blood product (packed red blood cells, platelet concentrates, or fresh‑frozen plasma) should be used?
How should a child with dengue fever and a platelet count below 20 × 10⁹/L be managed?
In a patient with dengue fever and severe thrombocytopenia, what investigations and severity scores should be performed?
How should I manage a 47-year-old white male non-smoker with LDL‑cholesterol 166 mg/dL, total cholesterol 242 mg/dL, HDL‑cholesterol 48 mg/dL, blood pressure 136/82 mm Hg on antihypertensive therapy, creatinine 1.3 mg/dL, and subclinical hypothyroidism?
What is the 10‑year ASCVD (Atherosclerotic Cardiovascular Disease) risk for a 47‑year‑old white male, non‑smoker, without diabetes, on antihypertensive medication, with systolic blood pressure 136 mm Hg, total cholesterol 242 mg/dL, HDL‑cholesterol 48 mg/dL, LDL‑cholesterol 166 mg/dL, and chronic kidney disease (creatinine 1.3 mg/dL)?
Which oil most closely resembles human sebum?
What is the clinical significance and recommended management of a hemorrhagic ovarian cyst in a reproductive‑age woman?
What is the appropriate management plan for a teenage girl with a hemorrhagic ovarian cyst, including size‑based treatment, pain control, and follow‑up?
What medications should be prescribed after a Rejuran (polynucleotide) injection procedure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.